Joint Formulary & PAD

Melatonin (Slenyto) - Sleep disorders in children and adolescents

You are here : Home > Formulary Search > Melatonin (Slenyto) - Sleep disorders in children and adolescents

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Modified release tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :

Documentation

Policy Statement
Melatonin (Slenyto) - Insomnia in children and adolescents - Policy statement APC 453-2019 - Oct 19

PAD Profile

ChemicalSubstance :
Melatonin (Slenyto)
Indication :
Sleep disorders in children and adolescents
Group Name :
Keywords :
Brand Names Include :
Slenyto
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

02 Oct 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey and North West Sussex Area Prescribing Committee (APC) does not recommend the use of melatonin (Slenyto) for the treatment of insomnia in children and adolescents (aged 2 – 18).


Melatonin (Slenyto) prolonged release tablets for this indication will be given a BLACK status (for all indications including the licensed status), on the traffic light system and is not recommended for use in any health setting across Surrey & North West Sussex health economy.

Other Indications

Below are listed other indications that Melatonin (Slenyto) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Sleep disorders in children and adolescents.